secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-001580
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027
--------------------------------------------------------------------------------

- 48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.
- As of Jan 2, 2026, 67.5M shares of common stock outstanding.
- 48.2M Series C warrants outstanding at $0.75 strike; if fully exercised could add $36.2M gross.
- Existing cash plus net proceeds from Series B exercise expected to fund operations into Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/0001193125-26-001580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/xlo-20260102.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer